205584-61-8

Basic information

• Product Name: 8-BROMO-2,3,4,5-TETRAHYDRO-1H-BENZO[B]AZEPINE HYDROCHLORIDE
• Synonyms: 8-BROMO-2,3,4,5-TETRAHYDRO-1H-BENZO[B]AZEPINE HYDROCHLORIDE;8-BroMo-2,3,4,5-tetrahydro-1H-benzo[b]azepine
• CAS NO: 205584-61-8
• Molecular Formula: C10H13BrClN
• Molecular Weight: 262.57392
• Mol File: 205584-61-8.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 8-BROMO-2,3,4,5-TETRAHYDRO-1H-BENZO[B]AZEPINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 8-BROMO-2,3,4,5-TETRAHYDRO-1H-BENZO[B]AZEPINE HYDROCHLORIDE(205584-61-8)
• EPA Substance Registry System: 8-BROMO-2,3,4,5-TETRAHYDRO-1H-BENZO[B]AZEPINE HYDROCHLORIDE(205584-61-8)

Safety Data

• Hazardous Substances Data: 205584-61-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
8-BROMO-2,3,4,5-TETRAHYDRO-1H-BENZO[B]AZEPINE HYDROCHLORIDE is used as a research chemical for the development of pharmaceutical drugs, particularly those targeting neurological and psychiatric disorders. Its ability to modulate neurotransmitter systems in the brain makes it a promising candidate for such applications.
Used in Neurological Disorders Treatment:
In the field of neurology, 8-BROMO-2,3,4,5-TETRAHYDRO-1H-BENZO[B]AZEPINE HYDROCHLORIDE is used as a potential therapeutic agent for the treatment of various neurological disorders. Its influence on neurotransmitter systems suggests it may help manage conditions related to imbalances or dysfunctions in these systems.
Used in Psychiatric Disorders Treatment:
8-BROMO-2,3,4,5-TETRAHYDRO-1H-BENZO[B]AZEPINE HYDROCHLORIDE is also used in psychiatry as a potential treatment for psychiatric disorders. Its modulation of neurotransmitter systems could contribute to the management of mental health conditions.
Used in Neuropharmacology Research:
In the area of neuropharmacology, 8-BROMO-2,3,4,5-TETRAHYDRO-1H-BENZO[B]AZEPINE HYDROCHLORIDE is used as a research tool to study the effects of drugs on the nervous system. Its interaction with neurotransmitter systems provides insights into drug mechanisms and potential therapeutic applications.
Used in Neurochemistry Studies:
8-BROMO-2,3,4,5-TETRAHYDRO-1H-BENZO[B]AZEPINE HYDROCHLORIDE is utilized in neurochemistry to explore the chemical processes and interactions within the nervous system. Understanding these processes can lead to the discovery of new drug targets and treatment strategies for neurological and psychiatric conditions.

Upstream product

• 877263-91-7 7-bromo-N-hydroxy-3,4-dihydronaphthalen-1(2H)-imine 
• 32281-97-3 7-bromo-3,4-dihydro-2H-naphthalen-1-one 
• 885953-12-8 8-bromo-1,3,4,5-tetrahydro-2H-benzo[b]azepin-2-one 

Relevant articles and documents

Design, synthesis and biological evaluation of brain penetrant benzazepine-based histone deacetylase 6 inhibitors for alleviating stroke-induced brain infarction

Histone deacetylase 6 (HDAC6) has become a promising therapeutic target for central nervous system diseases due to its more complex protein structure and biological functions. However, low brain penetration of reported HDAC6 inhibitors limits its clinical application in neurological disorders. Therefore, the benzazepine, a brain-penetrant rigid fragment, was utilized to design a series of selective HDAC6 inhibitors to improve brain bioavailability. Various synthetic strategies were applied to assemble the tetrahydro-benzazepine ring, and 22 compounds were synthesized. Among them, compound 5 showed low nanomolar potency and strong isozyme selectivity for the inhibition of HDAC6 (IC50 = 1.8 nM, 141-fold selectivity over HDAC1) with efficient binding patterns like coordination with the zinc ion and π-π stacking effect. Western blot results showed it could efficiently transport into SH-SY5Y cells and selectively enhance the acetylation level of α-tubulin with a moderate effect on Histone H3. Notably, pharmacokinetic studies demonstrated that compound 5 (brain/plasma ratio of 2.30) had an excellent ability to penetrate the blood-brain barrier of C57 mice. In male rats with transient middle cerebral artery occlusion (MCAO), compound 5 significantly reduced the cerebral infarction from 21.22% to 11.47% and alleviated neurobehavioral deficits in post-ischemic treatment, which provided a strong rationale for pursuing HDAC6-based therapies for ischemic stroke.

NOVEL COMPOUNDS

The present invention relates to novel NADPH oxidase II inhibitors and their use in the treatment of diseases mediated by the NADPH oxidase enzymes.

SULFONAMIDE DERIVATIVES

The invention is concerned with novel sulfonamide derivatives of formula (I) wherein R1, R2, R3, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit L-CPT1 and can be used as medicaments.

TRICYCLIC SPIRO-OXINDOLE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS

This invention is directed to tricyclic spiro-oxindole derivatives of formula (I), wherein j, k, m, n, w, q, Y, Q, X, R1, R2 and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of preparing and using the compounds are also disclosed.

Novel indolyl derivatives which are L-CPT1 inhibitors

The invention is concerned with novel heterobicyclic derivatives of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, A, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit L-CPT1 and can be used as medicaments.